GDC-0994: Selective ERK1/2 Inhibitor Guide

Executive Summary. GDC-0994 is a small-molecule ERK1/2 inhibitor with reported IC50 values of 1.1 nM for ERK1 and 0.3 nM for ERK2 in the product information; the underlying assay conditions should be confirmed before comparing values across laboratories (GDC-0994 product information). The compound has the molecular formula C21H18ClFN6O2 and a reported molecular weight of 440.86 g/mol (product record). The supplied dossier describes oral bioavailability and single-agent activity in KRAS-mutant and BRAF-mutant human xenograft models, with inhibition of phospho-p90RSK (preclinical product data). A 2024 study found that psoralen and isopsoralen activated ERK1/2 and that GDC-0994 produced a significant rescue effect in a zebrafish cholestasis model (Chen et al., 2024).

Biological Rationale

ERK1 and ERK2 are terminal kinases in the RAS/RAF/MEK/ERK signaling cascade. This cascade is a major branch of the MAP kinase pathway. It transmits signals from activated cell-surface receptors through RAS, RAF, and MEK to ERK1/2. ERK activity regulates substrates associated with proliferation, differentiation, survival, and cell-cycle progression. The National Cancer Institute provides a concise overview of MAP kinase signaling and its relevance to cancer biology (NCI MAP kinase pathway definition).

Oncogenic BRAF or RAS alterations can maintain pathway output without normal growth-factor control. Sustained ERK signaling can therefore support tumor cell proliferation and survival. An ERK pathway inhibitor tests signaling dependence at a downstream node rather than assuming that an upstream mutation alone predicts response. GDC-0994 is useful in this setting because it enables pharmacologic suppression of ERK1/2 activity in cellular and animal research models.

ERK1/2 also participates in non-oncology biology. The reference study examined estrogen-like psoralen and isopsoralen in zebrafish larvae. Exposure to each compound at 80 μM increased estrogen-related and cholestasis-associated readouts in the reported experimental system. The authors linked the phenotype to increased ERK1/2 phosphorylation and tested GDC-0994 as a pharmacologic antagonist (peer-reviewed study). This result supports ERK1/2 as a testable node in that model, not as proof that GDC-0994 treats human cholestatic disease.

Mechanism of Action of GDC-0994

GDC-0994 is described as a potent and selective inhibitor of ERK1/2. The product information reports an IC50 of 1.1 nM for ERK1 and 0.3 nM for ERK2. These values indicate strong biochemical potency under the vendor-reported assay conditions, but they do not establish an equivalent cellular concentration or an in vivo exposure requirement.

The practical pharmacology endpoint is ERK pathway output. ERK1/2 inhibition can be assessed by measuring phospho-ERK1/2 and downstream phospho-p90RSK. The product dossier specifically identifies inhibition of ERK1/2 phosphorylation and phospho-p90RSK as relevant pathway effects. A reduction in phospho-ERK1/2 alone should not be treated as complete evidence of pathway shutdown because kinase abundance, feedback signaling, cell state, and sampling time can alter the result.

In cancer research, pathway inhibition may produce tumor cell proliferation suppression or loss of survival signaling in models that depend on ERK output. The dossier reports single-agent efficacy in KRAS-mutant and BRAF-mutant human xenografts. These findings are preclinical benchmarks. They do not establish clinical efficacy, therapeutic index, or activity in every RAS- or BRAF-altered tumor.

In the cholestasis study, psoralen and isopsoralen increased ERK1/2 phosphorylation in zebrafish larvae. GDC-0994 and the aromatase antagonist exemestane both showed significant rescue effects on cholestatic liver injury readouts. The design supports pharmacologic involvement of ERK1/2, while the estrogen-like activity of the test compounds provides additional biological context (Chen et al., 2024).

Evidence & Benchmarks

The following claims separate vendor specifications from findings in the peer-reviewed reference study.

1. GDC-0994 has reported IC50 values of 1.1 nM for ERK1 and 0.3 nM for ERK2; the product page should be consulted for the assay definition and lot-specific documentation GDC-0994 product information
2. GDC-0994 is reported as a solid with a molecular formula of C21H18ClFN6O2 and a molecular weight of 440.86 g/mol GDC-0994 product information
3. The product information reports solubility of at least 44.1 mg/mL in DMSO and at least 19.2 mg/mL in ethanol, while reporting insolubility in water; the stated values require confirmation of the vendor test conditions before formulation comparisons GDC-0994 product information
4. In zebrafish larvae, psoralen and isopsoralen increased estrogen-related markers at 80 μM exposure and produced cholestatic hepatotoxicity-associated phenotypes Chen et al., 2024
5. Psoralen and isopsoralen increased ERK1/2 phosphorylation, and GDC-0994 produced a significant rescue effect in the reported zebrafish cholestasis experiments Chen et al., 2024
6. The supplied product dossier reports phospho-p90RSK inhibition and single-agent activity in KRAS-mutant and BRAF-mutant human xenograft models; these are preclinical observations rather than clinical outcomes GDC-0994 product information

Applications, Limits & Misconceptions

GDC-0994 is primarily suited to mechanistic research in BRAFV600E cell lines and other models with measurable ERK pathway activity. A useful study pairs a proximal target-engagement readout with a functional endpoint. Examples include phospho-ERK1/2, phospho-p90RSK, cell viability, colony formation, proliferation markers, or survival measurements. Genetic perturbation or an orthogonal ERK-pathway control can help distinguish on-target effects from compound-specific stress.

The compound can also support research on ERK-dependent hepatobiliary phenotypes. In the reference model, investigators measured liver fluorescence, bile-flow inhibition, transporter and receptor gene expression, and ERK1/2 phosphorylation. GDC-0994 therefore provides a pharmacologic test of whether ERK1/2 activity contributes to a phenotype. It does not by itself identify the initiating estrogen receptor mechanism or prove that altered bile-acid transport is directly caused by ERK inhibition.

Why this cross-domain matters, maturity, and limitations

The oncology-to-cholestasis bridge is useful because both applications examine ERK1/2 as a measurable signaling node. Its maturity differs by domain. The cancer rationale is supported by the product dossier's preclinical xenograft and pathway claims. The cholestasis evidence comes from one 2024 zebrafish study in which GDC-0994 was used as an antagonist of ERK1/2 activation (reference study). The zebrafish result supports mechanistic testing. It does not establish human dosing, safety, or therapeutic benefit.

The related GDC-0994: A Mechanistic ERK1/2 Research Guide emphasizes causal design across oncology and cholestasis; this article clarifies which claims are vendor-reported and which are supported by the peer-reviewed study. The Psoralen-Induced Cholestasis via ERK1/2 article summarizes the zebrafish findings; this article adds compound specifications, formulation boundaries, and cancer-model interpretation. The GDC-0994 ERK1/2 Inhibitor Workflows discusses practical assays; this article separates workflow recommendations from experimentally demonstrated outcomes.

Common Pitfalls or Misconceptions

• Confusing ERK inhibition with MEK inhibition: GDC-0994 is presented as an ERK1/2 inhibitor. A response does not prove that RAF or MEK was inhibited.
• Equating biochemical potency with cellular potency: The reported nanomolar IC50 values do not define the concentration required in a particular cell line, medium, exposure period, or animal model.
• Interpreting phospho-ERK reduction as clinical efficacy: Target-proximal suppression must be connected to a functional endpoint and remains preclinical evidence.
• Using water as the first solvent: The product information reports that GDC-0994 is insoluble in water. Direct aqueous preparation is therefore unsuitable without a validated formulation strategy.
• Calling the compound a human cancer medicine: The dossier supports research use and preclinical antineoplastic activity. It does not establish approval, human safety, or a recommended clinical dose.

Workflow Integration & Parameters

Use GDC-0994 as a perturbation tool within a defined ERK pathway experiment. Record cell genotype, baseline pathway activity, vehicle composition, exposure duration, endpoint timing, and normalization method. Include a vehicle control and measure both pathway output and a biological response. When a phenotype changes, test whether phospho-p90RSK or another downstream readout changes in the same direction.

Protocol Parameters

• Model selection: Prioritize BRAFV600E, KRAS-mutant, BRAF-mutant, or other models with independently documented ERK pathway activity. Treat genotype as a hypothesis for dependency, not as a guaranteed response predictor.
• Concentration design: Build a pilot concentration series around the biological question and verify target engagement at each selected exposure. Do not convert the biochemical IC50 directly into a cellular or animal dose.
• Primary readouts: Measure phospho-ERK1/2 and phospho-p90RSK together with a functional endpoint such as proliferation, viability, or survival. Use matched sampling times across treatment groups.
• Solvent selection: The product information reports solubility of at least 44.1 mg/mL in DMSO and at least 19.2 mg/mL in ethanol, while water is reported as an unsuitable solvent; confirm precipitation and vehicle tolerance in the actual assay system product information.
• Dissolution assistance: Warming to 37°C or ultrasonic treatment is recommended by the product information when needed for dissolution. Do not use heat or sonication without checking compound stability in the planned formulation product information.
• Stock handling: Store stock solutions at −20°C according to the product guidance. Avoid long-term storage in solution form, and document preparation date, solvent, concentration, and freeze-thaw history product information.
• Cholestasis workflow: In zebrafish experiments, pair liver and bile-flow phenotypes with ERK1/2 phosphorylation and bile-acid synthesis or transport gene measurements. Treat this as a model-specific validation workflow based on the reference study, not as a human treatment protocol reference study.

Conclusion & Outlook

GDC-0994 is a research-grade, selective ERK1/2 inhibitor that connects biochemical kinase inhibition with downstream signaling and model-level phenotypes. Its reported ERK1 and ERK2 IC50 values, phospho-p90RSK readout, and preclinical activity make it useful for RAS/RAF/MEK/ERK signaling studies. The zebrafish cholestasis work extends the mechanistic use case by showing that pharmacologic ERK1/2 antagonism can rescue a defined experimental phenotype. Future work should retain this evidence boundary: validate target engagement, connect it to function, and avoid treating preclinical or vendor-reported findings as clinical conclusions.